-
The INTERCEPT™ Blood System for Platelets and Plasma, Pathogen Reduction System
CANADA Region
-
The INTERCEPT™ Blood System for Platelets and Plasma, Pathogen Reduction System
CANADA Region
- 1
- 2
The INTERCEPT Blood System for Plasma and Platelets is approved in Canada.
The INTERCEPT Blood System for plasma is intended to be used for the ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma. The INTERCEPT Blood System for platelets is intended for the ex vivo treatment and storage of platelet components. The system is used to inactivate a broad range of pathogens, including viruses, bacteria, and protozoan parasites, thus reducing the risk of transfusion-transmitted infections (TTI).
Press Releases:
- Download the press release for plasma approval (English)
- Download the press release for platelet approval (English)
Package Inserts:
- Download the INTERCEPT Blood System for Plasma package insert
- Download the INTERCEPT Blood System for Platelets - Dual Storage (DS) package insert
- Download the INTERCEPT Blood System for Platelets - Large Volume (LV) package insert
- Download the INTERCEPT Blood System for Platelets - Small Volume (SV) package insert
Contact Us:
Phone: 1.855.835.3523
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Legal Info | Cookies Policy | Privacy Policy | Canada 
Rx Only. See package insert for CONTRAINDICATIONS and WARNINGS and full prescribing information. There is no pathogen inactivation process that has been shown to eliminate all pathogens. ©2019 Cerus Corporation. All Rights Reserved. INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation. This site is intended for Canadian audiences only. MKT-EN 00185 v2.0